AAPL   323.07 (-0.08%)
FB   230.93 (-0.77%)
GOOGL   1,441.48 (-0.06%)
AMZN   2,464.80 (-0.31%)
NVDA   353.30 (+0.08%)
MU   48.22 (+1.01%)
TSLA   880.84 (-0.08%)
AMD   53.27 (-0.17%)
T   31.43 (+1.42%)
ACB   14.69 (+1.10%)
F   5.94 (+0.68%)
GILD   73.82 (-2.51%)
DIS   119.40 (+0.55%)
NFLX   422.63 (-1.10%)
BAC   25.53 (+0.91%)
BA   156.82 (+2.29%)
AAPL   323.07 (-0.08%)
FB   230.93 (-0.77%)
GOOGL   1,441.48 (-0.06%)
AMZN   2,464.80 (-0.31%)
NVDA   353.30 (+0.08%)
MU   48.22 (+1.01%)
TSLA   880.84 (-0.08%)
AMD   53.27 (-0.17%)
T   31.43 (+1.42%)
ACB   14.69 (+1.10%)
F   5.94 (+0.68%)
GILD   73.82 (-2.51%)
DIS   119.40 (+0.55%)
NFLX   422.63 (-1.10%)
BAC   25.53 (+0.91%)
BA   156.82 (+2.29%)
AAPL   323.07 (-0.08%)
FB   230.93 (-0.77%)
GOOGL   1,441.48 (-0.06%)
AMZN   2,464.80 (-0.31%)
NVDA   353.30 (+0.08%)
MU   48.22 (+1.01%)
TSLA   880.84 (-0.08%)
AMD   53.27 (-0.17%)
T   31.43 (+1.42%)
ACB   14.69 (+1.10%)
F   5.94 (+0.68%)
GILD   73.82 (-2.51%)
DIS   119.40 (+0.55%)
NFLX   422.63 (-1.10%)
BAC   25.53 (+0.91%)
BA   156.82 (+2.29%)
AAPL   323.07 (-0.08%)
FB   230.93 (-0.77%)
GOOGL   1,441.48 (-0.06%)
AMZN   2,464.80 (-0.31%)
NVDA   353.30 (+0.08%)
MU   48.22 (+1.01%)
TSLA   880.84 (-0.08%)
AMD   53.27 (-0.17%)
T   31.43 (+1.42%)
ACB   14.69 (+1.10%)
F   5.94 (+0.68%)
GILD   73.82 (-2.51%)
DIS   119.40 (+0.55%)
NFLX   422.63 (-1.10%)
BAC   25.53 (+0.91%)
BA   156.82 (+2.29%)
Log in

NASDAQ:NKNantkwest Stock Price, Forecast & News

$7.49
-0.01 (-0.13 %)
(As of 06/3/2020 08:52 AM ET)
Add
Compare
Today's Range
$7.13
Now: $7.49
$7.76
50-Day Range
$2.99
MA: $4.46
$7.58
52-Week Range
$0.95
Now: $7.49
$9.90
Volume998,306 shs
Average Volume2.31 million shs
Market Capitalization$737.84 million
P/E RatioN/A
Dividend YieldN/A
Beta3.06
NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company's proprietary natural killer cells with Altor's ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Read More
Nantkwest logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.72 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone858-633-0300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$40,000.00
Price / Sales18,446.00
Book Value$1.23 per share

Profitability

Net Income$-65,790,000.00
Net Margins-112,350.85%

Miscellaneous

Employees161
Market Cap$737.84 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive NK News and Ratings via Email

Sign-up to receive the latest news and ratings for NK and its competitors with MarketBeat's FREE daily newsletter.

Nantkwest (NASDAQ:NK) Frequently Asked Questions

How has Nantkwest's stock been impacted by COVID-19 (Coronavirus)?

Nantkwest's stock was trading at $3.52 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NK stock has increased by 112.8% and is now trading at $7.49. View which stocks have been most impacted by Coronavirus.

When is Nantkwest's next earnings date?

Nantkwest is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Nantkwest.

How were Nantkwest's earnings last quarter?

Nantkwest Inc (NASDAQ:NK) issued its quarterly earnings data on Monday, May, 11th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.17) by $0.02. The biotechnology company earned $0.02 million during the quarter. Nantkwest had a negative net margin of 112,350.85% and a negative return on equity of 51.94%. View Nantkwest's earnings history.

Has Nantkwest been receiving favorable news coverage?

Media stories about NK stock have been trending positive on Wednesday, according to InfoTrie. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Nantkwest earned a news sentiment score of 2.4 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutNantkwest.

Are investors shorting Nantkwest?

Nantkwest saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 4,910,000 shares, an increase of 35.3% from the April 30th total of 3,630,000 shares. Based on an average daily trading volume, of 922,300 shares, the short-interest ratio is presently 5.3 days. Currently, 17.7% of the company's stock are short sold. View Nantkwest's Current Options Chain.

Who are some of Nantkwest's key competitors?

What other stocks do shareholders of Nantkwest own?

Who are Nantkwest's key executives?

Nantkwest's management team includes the following people:
  • Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 66)
  • Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 54)
  • Mr. Richard J. Tajak, Consultant (Age 66)
  • Ms. Sonja Nelson, CFO & Principal Financial Officer (Age 46)
  • Mr. David J. Pyrce, Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 62)

When did Nantkwest IPO?

(NK) raised $150 million in an IPO on Tuesday, July 28th 2015. The company issued 7,000,000 shares at $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray served as the underwriters for the IPO and MLV & Co. was co-manager.

What is Nantkwest's stock symbol?

Nantkwest trades on the NASDAQ under the ticker symbol "NK."

Who are Nantkwest's major shareholders?

Nantkwest's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (0.69%), Geode Capital Management LLC (0.33%), Morgan Stanley (0.07%), Horizon Kinetics Asset Management LLC (0.05%), Creative Planning (0.05%) and Two Sigma Investments LP (0.04%). Company insiders that own Nantkwest stock include Barry J Simon, John C Thomas and Steve Gorlin. View institutional ownership trends for Nantkwest.

Which institutional investors are selling Nantkwest stock?

NK stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Horizon Kinetics Asset Management LLC, First Allied Advisory Services Inc., BlackRock Inc., and State Street Corp. Company insiders that have sold Nantkwest company stock in the last year include Barry J Simon, and John C Thomas. View insider buying and selling activity for Nantkwest.

Which institutional investors are buying Nantkwest stock?

NK stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Two Sigma Investments LP, Deutsche Bank AG, Geode Capital Management LLC, Creative Planning, Invesco Ltd., Squarepoint Ops LLC, and GSA Capital Partners LLP. View insider buying and selling activity for Nantkwest.

How do I buy shares of Nantkwest?

Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Nantkwest's stock price today?

One share of NK stock can currently be purchased for approximately $7.49.

How big of a company is Nantkwest?

Nantkwest has a market capitalization of $737.84 million and generates $40,000.00 in revenue each year. The biotechnology company earns $-65,790,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Nantkwest employs 161 workers across the globe.

What is Nantkwest's official website?

The official website for Nantkwest is www.nantkwest.com.

How can I contact Nantkwest?

Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.